Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India

Sarthak Sharma 1, Shaitan Singh Rathore 1, Vijay Verma 1, Murlidhar Kalyan 1, Narender Singh 1, Irshad Irshad 1

1. General Surgery, Dr. Sampurnanand Medical College, Jodhpur, IND

Corresponding author: Sarthak Sharma, sarthak0504@gmail.com

Abstract

Introduction: Locally advanced breast cancer (LABC) is a subset of breast cancer characterized by the most advanced breast tumours in the absence of distant metastasis. Treatment of LABC has evolved from a single modality treatment to multimodality management. Neoadjuvant chemotherapy (NACT) is increasingly being used to treat patients with LABC. This study assessed tumour response after NACT using clinical changes, Response Evaluation Criteria in Solid Tumors (RECIST) criteria and pathological report.

Methodology: This study was a prospective as well as retrospective observational study carried out in the department of general surgery, Dr. Sampurnanand Medical College, Jodhpur. All the patients admitted with stage III (IIIA, IIIB, IIIC) were included in the study after obtaining approval from the institutional ethical committee. Clinical response was assessed by RECIST criteria (clinical complete response (cCR), clinical partial response (cPR), clinical progressive disease (cPD), and clinical stable disease (cSD)) and pathological response by histopathological report (pCR). Response of various molecular subtypes was noted.

Results: Among 31 patients included in the study, cCR observed in 22.58% cases, cPR observed in 61.29% cases while cPD and cSD seen in 3.22% and 12.90% cases, respectively. Pathological complete response (pCR) observed in 19.35% cases. Favourable response seen with human epidermal growth factor receptor 2 (HER2) overexpression (cCR = 50%, pCR = 37.50%) followed by triple negative (cCR = 25%, pCR = 25%) molecular subtypes.

Conclusions: It can be concluded that molecular subtype determination helps in deciding treatment protocol in patients with LABC with HER2 overexpression and triple-negative breast cancers having a better clinicopathological response to NACT than luminal subtypes. NACT results in downstaging of tumours, thus, help in achieving surgically clear margins and elimination of micrometastases which decreases the recurrence rates and morbidity/mortality of patients.

Introduction

Breast cancer is the most commonly diagnosed cancer and the fifth cause of cancer deaths in the world, with an estimated 2.3 million cases and 685,000 deaths in 2020 [1]. Breast cancer in India accounts for 14% of all cancers in women. The incidence rates in India begin to rise in the early 30s and peak at ages 50-64 years [2].

Locally advanced breast cancer (LABC) represents an important and challenging problem. The US National Comprehensive Cancer Network (NCCN) describe LABC as American Joint Committee on Cancer (AJCC) stage III breast cancer that includes: tumours >5 cm (T3) with regional lymphadenopathy (N1-3), tumours of any size with chest wall or skin or both involvement (T4) irrespective of lymph node status, extensive lymph nodes involvement (matted axillary lymph nodes, or any of infra-clavicular, supra-clavicular, or internal mammary) [3].

Neoadjuvant chemotherapy (NACT) has become a primary option for patients with LABC [4]. The rationale for using NACT is to improve surgical options and to gain information on drug response by in-breast assessment. Furthermore, NACT provides the opportunity to discover predictive markers of chemotherapy [4]. The pathological complete response (pCR) is considered a biological marker for survival outcomes. The pCR is considered when there is complete eradication of locoregional disease [5,6].
We conducted this study in females with stage III LABC to evaluate the clinical response (Response Evaluation Criteria in Solid Tumors (RECIST) criteria) and pathological response shown by various molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple negative) to NACT.

**Materials And Methods**

The study was a prospective and retrospective observational study conducted in the department of general surgery, Mathura Das Mathur Hospital affiliated with Dr. Sampuranand Medical College, Jodhpur, Rajasthan. Institutional Ethics Committee, Dr. Sampuranand Medical College, Jodhpur issued approval SNMC /IEC/395 before the initiation of the study. Response rates were taken as the endpoint of the study.

After applying inclusion and exclusion criteria, 31 patients were identified for the study (Table 1). Initial staging workup included clinical examination supplemented by haematological (complete blood count), biochemical (renal and liver function tests), and radiological investigations (X-ray-chest, skeletal survey, and ultrasound abdomen). Computed tomography and magnetic resonance imaging were done wherever indicated. Immunohistochemistry was obtained for all the patients.

| Inclusion Criteria                                                                 | Exclusion Criteria                                                                 |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Previously untreated female patients with bi-dimensionally palpable and measurable primary breast cancer stage III (according to AJCC TNM staging system, 8th edition) diagnosed by core needle biopsy. | Patient not willing for study;                                 |
|                                                                                  | All cases diagnosed as benign disease of breast;                                |
|                                                                                  | Breast carcinoma patients not lying in the definition of locally advanced breast cancer (LABC) clinically and/or radiologically; |
|                                                                                  | All patients with presence of distant metastasis proved on clinical examination/investigations. |

**TABLE 1: Inclusion and exclusion criteria**

AJCC: American Joint Committee on Cancer; TNM: tumour, node, metastasis

Patients were subjected to anthracycline-based NACT after the initial assessment was completed. Chemotherapy consisted of Adriamycin 60 mg/m² body surface area (BSA) IV over 3 hours and cyclophosphamide 600 mg/m² BSA IV over 3 hours. All patients received four cycles of NACT (q21 days). All the patients were subjected to modified radical mastectomy (MRM) after NACT and specimens were sent for histopathological examination (HPE).

**Evaluation of neoadjuvant chemotherapy response**

Clinical response was assessed by RECIST criteria (Table 2).

| RECIST Criteria                  | Clinical complete response (cCR)                                      |
|---------------------------------|---------------------------------------------------------------------|
|                                 | No palpable tumour in the breast and axilla                         |
| Clinical partial response (cPR) | ≥30% reduction in the maximum dimension of the tumour mass          |
| Clinical progressive disease (cPD) | ≥20% increase in the maximum dimension of tumour mass               |
| Clinical stable disease (cSD)   | When the change does not meet any of the other criteria             |

**TABLE 2: RECIST criteria**

RECIST: Response Evaluation Criteria in Solid Tumors

Pathological response was assessed by histopathology. pCR implied no residual invasive breast cancer in the histopathology specimen of breast and axillary lymph nodes (ypT0/ypTisN0). All comparisons of categorical variables were performed with the chi-square test while continuous variables were compared using the t-
test. All the results are presented with p-values.

**Results**

The median age of the patients at the time of diagnosis was 49 years (range: 25-79 years). The maximum number of patients were in the age group of 41-50 years (41.93%) followed by 51-60 years (25.80%). 61.29% were premenopausal at the time of diagnosis. The clinical characteristics are listed in Table 3.

| Characteristics           | Number of patients (n=31) |
|---------------------------|---------------------------|
| Age (years), median (range)| 49 (25-79)                |
| Menopausal status         |                           |
| Premenopausal             | 19 (61.29%)               |
| Post-menopausal           | 12 (38.71%)               |
| Lump laterality           |                           |
| Right                     | 18 (58.06%)               |
| Left                      | 13 (41.94%)               |
| Lump size                 |                           |
| <5 cm                     | 2 (6.45%)                 |
| >5 cm                     | 29 (93.54%)               |
| Nodal status              |                           |
| Negative                  | 0                         |
| Positive                  | 31 (100%)                 |
| Clinical stage            |                           |
| III A                     | 18 (58.06%)               |
| III B                     | 11 (35.48%)               |
| III C                     | 2 (6.45%)                 |
| Histological type         |                           |
| Invasive ductal carcinoma | 28 (90.32%)               |
| Invasive lobular carcinoma| 1 (3.23%)                 |
| Others                    | 2 (6.45%)                 |
| Molecular classification   |                           |
| Luminal A                 | 10 (32.26%)               |
| Luminal B                 | 5 (16.13%)                |
| HER2 overexpression        | 8 (25.81%)                |
| Triple negative           | 8 (25.81%)                |

**TABLE 3: Clinicopathological characteristics of the patients and molecular subtypes**

HER2: human epidermal growth factor receptor 2

The lump was the most consistent presenting symptom and was present in 100% of the cases. The upper outer quadrant (58.06%) was the most commonly involved quadrant and the least incidence was found in the lower inner quadrant (3.23%). The tumour size ranged from 4 to 12.5 cm with a mean size of 6.11 cm. All the patients were lymph node positive at the time of presentation. 90.32% patients had invasive ductal carcinoma (IDC).
Clinical and pathological response rates according to molecular subtypes

A clinical response was observed in 83.87% of the cases subjected to NACT as assessed by RECIST criteria with clinical complete response (cCR) noted in 22.58% cases. 51.61% cases became clinically lymph node-negative following NACT (p value <0.0001) and clinical downstaging was observed in 67.74% cases (p value <0.0001). The response shown by various molecular subtypes is listed in Table 4.

| Subtype               | cCR        | cPR        | cPD        | cSD        |
|-----------------------|------------|------------|------------|------------|
| Luminal A             | 1 (10.00%) | 7 (70.00%) | 1 (10.00%) | 1 (10.00%) |
| Luminal B             | 0 (0.00%)  | 4 (80.00%) | 0 (0.00%)  | 1 (20.00%) |
| HER2 overexpression    | 4 (50.00%) | 3 (37.50%) | 0 (0.00%)  | 1 (12.50%) |
| Triple Negative       | 2 (25.00%) | 5 (62.50%) | 0 (0.00%)  | 1 (12.50%) |
| Total                 | 7 (22.58%) | 19 (61.29%)| 1 (3.22%)  | 4 (12.90%) |

*TABLE 4: Clinical Response Rates in Molecular Subtypes*

cCR: clinical complete response; cPR: clinical partial response; cPD: clinical progressive disease; cSD: clinical stable disease; HER2: human epidermal growth factor receptor 2

CcCR was observed in a maximum of 50% of the cases of HER2 overexpression followed by 25% of cases of triple-negative breast cancer. No cCR was noted in luminal B subtype. pCR was observed in 19.35% cases included in the study. The rates of pCR in different molecular subtypes are depicted in Table 5.

| Subtype              | pCR        | No pCR     |
|----------------------|------------|------------|
| Luminal A            | 1 (10.00%) | 9 (90.00%) |
| Luminal B            | 0 (0.00%)  | 5 (100%)   |
| HER2 overexpression   | 3 (37.50%) | 5 (62.50%) |
| Triple negative      | 2 (25.00%) | 6 (75.00%) |

*TABLE 5: Pathological response rates in molecular subtypes*

HER2: human epidermal growth factor receptor 2

Maximum (37.50%) pCR was observed in the HER2 overexpression subtype followed by 25% in the triple-negative subtype. No pCR was observed in luminal B subtype. An observation regarding the common side-effects of chemotherapeutic drugs was made. Alopecia was the most common side effect which was present in 100% cases followed by anaemia (58.06%), nausea and vomiting (45.16%), and neutropenia (38.71%).

**Discussion**

LABC poses a challenge to the treating surgeon in terms of choosing the appropriate treatment for his/her patient. With advances in cancer management, especially breast cancer, with the availability of systemic and hormonal therapies and breast conservation surgery, it has become important to individualize patient’s treatment.

There has been a constant debate regarding NACT’s role in LABC. Neoadjuvant chemotherapy leads to cytodestruction of the primary tumour and regional lymph nodes allowing breast conservation in selected cases. An additional benefit of this technique is, potentially, eradication of distant microscopic metastases, the presence of which is the most common cause of relapse. Moreover, early application of chemotherapy may also guide postoperative therapeutic options by evaluating a tumour’s chemosensitivity. However, it is feared that delaying the initiation of definitive therapy for operable LABC, if the tumour burden is large, might lead to the development of drug resistance and subsequently systemic metastases. Besides, toxicity from early use of chemotherapy might render a patient a nonsurgical candidate [7].
In our study, 31 patients were included who had a diagnosis of stage III LABC at the time of presentation. The maximum number of patients were in the age group of 41-50 years (41.93%) followed by 51-60 years (25.80%) and median age was 49 years. This age distribution of patients was similar to previous studies [8,9,10]. A lump in the breast was the commonest symptom noticed in 100% cases in our study which was similar to other studies [11,12,13]. Upper outer quadrant (58.06%) was the most commonly involved quadrant and the least incidence was found in lower inner quadrant (5.23%). The tumour size ranged from 4 to 12.5 cm with a mean size of 6.11 cm. All the patients were lymph node positive at the time of presentation. 90.32% of patients had IDC.

Gene expression studies have identified distinct molecular subtypes of breast cancer with a different prognoses [14,15,16]. It is also believed that various subtypes of breast cancer show different sensitivities to systemic chemotherapy. In the present study, we used molecular classification and divided patients into four subtypes: luminal A, luminal B, HER2 overexpression, and triple-negative and assessed the response of each subtype to anthracycline-based NACT.

Clinical response was assessed by calculating the percentage decrease in the volume of the tumour. The overall response to NACT in this study was 85.87% with partial response seen in 61.29% cases and complete response seen in 22.58% cases which was similar to previous studies [17,18]. 51.61% of cases became clinically lymph node-negative following NACT (p value <0.0001).

CPR was seen in maximum 50% cases of HER2 overexpression followed by 25% cases of triple-negative breast cancer while luminal types had low cCR rates with no cCR seen in luminal B subtype. Clinical partial response (cPR) was observed in 70% of luminal A, 80% of luminal B, 62.50% of triple negative, and 37.50% of HER2 overexpression subtype.

The pathological response was assessed by the HPE of the MRM specimen. pCR was noted in 19.35% cases. Among molecular subtypes, maximum of 37.50% pCR was observed in HER2 overexpression followed by 25% cases of triple-negative subtype. No pCR was observed in luminal B subtype. Gentile et al. in their study observed pCR in 48% cases of HER2 overexpression and 25% cases of triple-negative breast cancer [19]. Luangdilok et al. and Subbiah et al. also showed that HER2 overexpression and triple-negative breast cancer subtypes had more pCR as compared to luminal subtypes [20,21].

There are multiple potential reasons that the response to chemotherapy differed by subtype. The triple-negative and HER2 overexpression breast cancers are characterized by the high expression of the proliferation cluster of genes [14,15]. Furthermore, the triple-negative tumour is basically estrogen/progesterone (ER/PR) negative, and evidence suggests that the negative hormone receptor status is one of the strongest predictive markers associated with the higher likelihood of pCR to NACT [22,23,24].

Chemotherapy has got its own complications and incidence wise alopecia, anaemia, nausea and vomiting are the commonest. In the present study, alopecia was the most common side effect which was present in 100% cases followed by anaemia (58.06%), nausea and vomiting (45.16%), and neutropenia (38.71%).

Limitations of study: The study was conducted in a single institution and had a small sample size.

Conclusions

LABC is a common presentation of carcinoma breast in India and the role of NACT has been debated for a long time now. In our study, clinical response (complete plus partial) resulting in a decrease in tumour size was observed in more than 80% cases. Pathological disappearance of the invasive tumour was noted in approximately 20% cases.

Assessment of response of molecular subtypes to NACT suggests that HER2 overexpression and triple-negative breast cancers have better clinicopathological response than luminal subtypes. Hence, molecular subtype determination helps in deciding treatment protocol in patients with LABC. NACT results in downstaging of tumours, thus, help in achieving surgically clear margins and elimination of micrometastases which decreases the recurrence rates and morbidity/mortality of patients.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, Dr. Sampuranand Medical College, Jodhpur issued approval SNMC/IEC/395. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Lei S, Zheng R, Zhang S, et al.: Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021, 41:1183-94. 10.1002/cac2.12207
2. Definition of LABC. (2022). Accessed: April 24, 2022: http://cancerindia.org.in/cancer-statistics/.
3. Gradishar WJ, Anderson BO, Balassanian R, et al.: Breast cancer version 2.2015. J Natl Compr Canc Netw. 2015, 13:448-75. 10.6004/jncrn.2015.0060
4. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW: Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010, 79:324-50. 10.1159/000352192
5. Iqbal J, Banu K, Saeed A, Akram M, Aziz Z: Survival of women with locally advanced breast cancer at a teaching hospital in Lahore. J Pak Med Assoc. 2010, 60:721-5.
6. Buzdar AU: Preoperative chemotherapy treatment of breast cancer—a review. Cancer. 2007, 110:2394-407. 10.1002/cncr.23083
7. Dee SV, Bhutani M, Shukla NK, Raina V, Rath GK, Purkayastha J: Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol. 2005, 84:192-7. 10.1002/jso.10323
8. Chopra R: The Indian scene. J Clin Oncol. 2001, 19:106-11.
9. Goel A, Bhan CM, Srivastava KN: Five year clinicopathological study of breast cancer. Indian J Med Sci. 2005, 57:347-9.
10. Sen AK, Gupta DTK: Cancer of the breast and its treatment. Indian J Surg. 2009, 11:832-47.
11. Viswanabhavan JR, Kadambari D, Iyergr KR, Srinivasan K: Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy. Indian J Cancer. 2005, 42:50-4. 10.4102/0019-509x.15097
12. Yadav BS, Sharma SC, Singh R, Singh G: Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther. 2007, 3:75-80. 10.4103/0973-1412.34683
13. Kuraparthys S, Reddy KM, Yadagiri LA, Yatla M, Venkata PB, Kadainti SV, Reddy RP: Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol. 2007, 5:56. 10.1186/1477-7819-5-56
14. Perou CM, Sariie T, Eiser MB, et al.: Molecular portraits of human breast tumours. Nature. 2000, 406:747-52. 10.1038/35021095
15. Sariie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98:10869-74. 10.1073/pnas.191367098
16. Sariie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2005, 100:8418-23. 10.1073/pnas.05095269100
17. Gedam MC, Shukla K, Ingale LY: Clinical presentation and management of locally advanced breast carcinoma. Int Surg J. 2018, 5:3690-4. 10.18203/2349-2902.isj20184646
18. Siddhartha T, Kanchana B: A study on role of neo adjuvant chemotherapy in locally advanced non-metastatic breast cancer. Int Surg J. 2018, 5:2110-3. 10.18203/2349-2902.isj20181999
19. Gentile LF, Pitias G, Zabor EC, StempeL M, Morrow M, Barrio AV: Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Ann Surg Oncol. 2017, 24:5896-902. 10.1245/s10434-017-6085-y
20. Luangdilok S, Samarnthai N, Korphaisarn K: Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014, 17:376-85. 10.4048/jbc.2014.17.4.376
21. Subbliah S, Gopu G, Senthikumar P, Municamay P: Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. Indian J Cancer. 2017, 54:652-7. 10.4103/ic-ic.123_17
22. Maur M, Guernei V, Frassoldati A, Conte PF: Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. Ann Oncol. 2006, 17:158-64. 10.1093/annonc/mdl973
23. Burcombe RJ, Makris A, Richman PI, et al.: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005, 92:147-55. 10.1038/sj.bjc.6602556
24. Petit T, Wilt M, Velten M, et al.: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004, 40:205-11. 10.1016/S0959-8049(03)00675-0